Diagnostic accuracy of MRI in assessing tumor regression and identifying complete response in patients with locally advanced rectal cancer after neoadjuvant treatment

被引:31
|
作者
Aker, Medhat [1 ,2 ]
Boone, Darren [1 ]
Chandramohan, Anuradha [1 ]
Sizer, Bruce [1 ]
Motson, Roger [1 ]
Arulampalam, Tan [1 ]
机构
[1] Colchester Gen Hosp, Colchester CO4 5JL, Essex, England
[2] Colchester Gen Hosp, ICENI Ctr, Colchester CO4 5JL, Essex, England
关键词
Accuracy; MRI; Neoadjuvant treatment; Chemo-radiotherapy; Complete response; Tumor regression grade; CHEMORADIOTHERAPY; OUTCOMES; SURGERY;
D O I
10.1007/s00261-018-1627-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundThe diagnostic accuracy of Magnetic Resonance Imaging (MRI) in restaging locally advanced rectal cancers (LARC) after neoadjuvant chemo-radio therapy (NCRT) has been under recent scrutiny. There is limited data on the accuracy of MRI and its timing in assessing tumor regression grade (TRG) and in identifying patients with complete response (CR). NCRT seems to cause tissue inflammation and oedema which renders reading the scans difficult for radiologist.AimThis study aims to assess the accuracy of MRI at different time intervals after NCRT in staging TRG and in identifying CR. Inter-observer agreement between 2 blinded radiologists will also be assessed.MethodIn this retrospective analysis, all patients diagnosed with LARC between January 2003 and 2014, who underwent long-course NCRT, who had at least one post-treatment MRI scan, and who underwent surgery with available pathology results are included. Histopathology staging is considered the reference standard. Accuracy of MRI in T staging and in TRG staging is assessed using weighted kappa. Accuracy, sensitivity, and specificity in identifying CR are calculated from a 2x2 contingency table. Inter-observer agreement between two-staging blinded radiologists is calculated using weighted kappa. These are calculated at 2 different time intervals after completion of NCRT.Results114 patients were identified who had a first post-treatment MRI scan at an average of 6.2weeks after completion of NCRT. A subgroup of 68 patients had a second post-treatment MRI at an average of 10.4weeks. Pathology results were available for 103 patients. By the second post-treatment scan, an additional 25% of patients experienced downstaging; accuracy in T staging increased from 43% to 57.4%; accuracy in TRG staging rose from 28.2% to 38.1%; accuracy in identifying CR rose from 83.4% to 84.1%. Inter-observer agreement in T staging rose from 0.1 for first post-treatment MRI to 0.206 for second post-treatment MRI.ConclusionThis study advocates that restaging should occur at 10weeks rather than the standard 6weeks. This results in higher complete response rates and higher concordance with pathological specimens. Our results also showed that it is easier for radiologists to stage the MRI scans, resulting in higher inter-rater agreements.
引用
收藏
页码:3213 / 3219
页数:7
相关论文
共 50 条
  • [1] Diagnostic accuracy of MRI in assessing tumor regression and identifying complete response in patients with locally advanced rectal cancer after neoadjuvant treatment
    Medhat Aker
    Darren Boone
    Anuradha Chandramohan
    Bruce Sizer
    Roger Motson
    Tan Arulampalam
    Abdominal Radiology, 2018, 43 : 3213 - 3219
  • [2] MRI Evaluation of Complete and Near-Complete Response after Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer
    Popita, Anca-Raluca
    Lisencu, Cosmin
    Rusu, Adriana
    Popita, Cristian
    Cainap, Calin
    Irimie, Alexandru
    Resiga, Liliana
    Munteanu, Alina
    Fekete, Zsolt
    Badea, Radu
    DIAGNOSTICS, 2022, 12 (04)
  • [3] Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
    Zhang, Jianwei
    Cai, Jian
    Deng, Yanhong
    Wang, Hui
    ONCOIMMUNOLOGY, 2019, 8 (12):
  • [4] Compatibility of MRI and Pathological Tumor Regression Grading in Patients with Locally Advanced Rectal Cancer After Undergoing Neoadjuvant Chemoradiotherapy
    Arslan, Alaettin
    Turk, Gamze
    Eren, Saliha Karagoz
    Akay, Ebru
    Ozhan, Nail
    Aral, Ipek Pinar
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (04): : 468 - 477
  • [5] Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer
    Chandramohan, Anuradha
    Siddiqi, Umar M.
    Mittal, Rohin
    Eapen, Anu
    Jesudason, Mark R.
    Ram, Thomas S.
    Singh, Ashish
    Masih, Dipti
    EUROPEAN JOURNAL OF RADIOLOGY OPEN, 2020, 7
  • [6] Magnetic Resonance Texture Analysis in Identifying Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
    Aker, Medhat
    Ganeshan, Balaji
    Afaq, Asim
    Wan, Simon
    Groves, Ashley M.
    Arulampalam, Tan
    DISEASES OF THE COLON & RECTUM, 2019, 62 (02) : 163 - 170
  • [7] MRI Evaluation of Complete Response of Locally Advanced Rectal Cancer After Neoadjuvant Therapy: Current Status and Future Trends
    Xu, Qiaoyu
    Xu, Yanyan
    Sun, Hongliang
    Jiang, Tao
    Xie, Sheng
    Ooi, Bee Yen
    Ding, Yi
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4317 - 4328
  • [8] Nodal involvement in luminal complete response after neoadjuvant treatment for rectal cancer
    Loftas, P.
    Arbman, G.
    Fomichov, V.
    Hallbook, O.
    EJSO, 2016, 42 (06): : 801 - 807
  • [9] Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer
    Nahas, Sergio Carlos
    Rizkallah Nahas, Caio Sergio
    Cama, Gerson Montoya
    de Azambuja, Rodrigo Lautert
    Horvat, Natally
    Sparapan Marques, Carlos Frederico
    Menezes, Marcos Roberto
    Ribeiro Junior, Ulysses
    Cecconello, Ivan
    ABDOMINAL RADIOLOGY, 2019, 44 (11) : 3632 - 3640
  • [10] Prediction of pathologic complete response to neoadjuvant chemoradiation in locally advanced rectal cancer
    Zhong, Xiaoling
    Zeng, Guohua
    Zhang, Lixiang
    You, Shuyuan
    Fu, Yuxiang
    He, Wan
    Liao, Guixiang
    FRONTIERS IN ONCOLOGY, 2024, 14